STRUCTURAL HEART
CoreValve Evolut-R TAVR (26mm) via Percutaneous Femoral Access – Aug 2015

An 88 year-old female presented with progressive shortness of breath – NYHA class III, with a history of hypertension, chronic diastolic HF, COPD and s/p BAV on 7/2/15. TTE revealed severe AS, peak/mean aortic gradient = 65/44 mmHg, AVA = 0.6 sq cm, aortic peak velocity = 4 m/sec and LVEF 65%. CT angio showed minimum diameters of 0.4 x 0.7 cm for right and 0.6 x 0.6 cm for the left common femoral arteries and aortic annulus of 2.5 x 2.1 cm (average 2.3). The STS risk mortality is 5.15 and the Logistic Euroscore mortality is 12.81. Patient was determined to be extreme risk for surgical AVR due to advanced age and marked, generalized frailty. Patient is now planned for CoreValve Evolut R TAVR (26mm) via percutaneous femoral access under conscious sedation.

 

46:50

comments

Leave Your Comments

suggestion
Suggestions
Valve-in-Valve TAVR with 26mm SAPIEN-3 – March 2019
Views247

79 year old man presents with worsening exertional dyspnea (NYHA Class III) for the last 3 months. Patient has required […]


50:31
Valve-in-Valve TAVR with 29mm Evolut-R CoreValve – January 2019
Views467

79 year old man presents with progressive exertional dyspnea (NYHA Class III) for the last 2 months.


1:07:06
TAVR 29mm Sapien-3 – November 2018
Tags:
Views670

96 year old male presents with progressive exertional dyspnea (NYHA Class III) for the last 4 months.


49:42
TAVR in a Patient with Prior Mitral Valve Replacement – September 2018
Tags: |
Views649

87 year old female presents with progressive exertional dyspnea (NYHA Class III) for the last 3 months.